产品特点
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Lariam 250mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 250mg mefloquine (as 274.09 mg mefloquine hydrochloride).
Each tablet contains 50.61mg lactose monohydrate
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablets
White to off-white cylindrical biplanar tablets, cross-scored and imprinted Roche on one face.
The tablet can be divided into equal halves to facilitate dosing.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Therapy and prophylaxis of malaria.
_Therapy_: Lariam is especially indicated for therapy of _P. falciparum _malaria in which the pathogen has become
resistant to other antimalarial agents.
Following treatment of _P. vivax _malaria with Lariam, relapse prophylaxis with an 8-amino-quinoline derivative, for
example primaquine, should be considered in order to eliminate parasites in the hepatic phase.
_Prophylaxis_: Malaria prophylaxis with Lariam is particularly recommended for travellers to malarious areas in which
multiple resistant _P. falciparum _strains occur.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_CURATIVE TREATMENT_
The recommended total therapeutic dose of mefloquine for non-immune patients is 20 – 25mg/kg. A lower total dose
of 15mg/kg may suffice for partially immune individuals.
The recommended total therapeutic dosages of Lariam tablets relative to body weight and immune status are presented
in the following table:*
NON-IMMUNE PATIENTS
PARTIALLY IMMUNE
PATIENTS
< 20kg **
¼ tablet / 2.5 – 3kg
1 tablet / 10 – 12 kg
¼ tablet / 4kg
1 tablet / 16kg
20 - 30kg
2 – 3 tablets
1¼ - 2 tablets
> 30 - 45kg
3 – 4 tablets
2 – 3 tablets
> 45 – 60kg
4 – 5 tablets
3 – 4 tablets
> 60kg ***
6 tablets
4 – 6 tablets
IRISH MEDICIN
阅读完整的文件
产品特点 